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We considered several key issues regarding the development of a DNA-based human immunodeficiency virus type 1
(HIV-1) vaccine: (1) should the candidate vaccine construct be derived from incident or prevalent HIV-1 strains; and (2) should
circulating plasma virus, archived HIV-1 provirus recovered from peripheral blood mononuclear cells, or both be included?
To address these questions, we collected circulating HIV-1 strains from infected individuals residing in Abidjan, Coˆte d’Ivoire.
From a panel of 23 strains, 22 were HIV-1 subtype A in gag, 19 of which phylogenetically clustered with the recombinant
HIV-1, CRF02-AG strains from West Africa. The mosaic genome of CRF02-AG was confirmed by sequencing the protease
gene. A consensus gag p24 protein sequence was generated and 147 of 148 codons were identical to CRF02-AG (IbNG).
Regardless of the sequence origin (RNA, provirus, incident, or prevalent), the gag p24 consensus sequences were highly
representative of these distinct virologic compartments. These data suggest that the consensus sequence generated from
incident and prevalent infections may provide an appropriate sequence for a DNA vaccine and is largely representative ofINTRODUCTION
Although many HIV-1 candidate vaccines have ad-
vanced in development, a vaccine that is effective
against HIV-1 transmission remains urgently needed as
an estimated 40 million people of the world’s population
may be infected (Moore, 2002). While prevention (steril-
izing immunity) of HIV-1 infection still seems remote,
effective vaccination may potentially prevent transmis-
sion and slow disease progression. Knowledge of the
predominant HIV-1 subtype, sub-subtypes, and circulat-
ing recombinant forms (CRF) in a targeted population
1 Presented in part at the 1st Annual International Conference on HIV
and Immunotherapies, Palm Beach, FL, June 28–July 1, 2000 (Abstract
No. 63). This study was carried out under an approved protocol in
accordance with guidelines set forth by the Centers for Disease Control
and Prevention.
2 Note: Use of trade names is for identification only and does not
constitute endorsement by the U.S. Department of Health and Human
Services, the Public Health Service, or the Centers for Disease Control
and Prevention.
3 To whom correspondence and reprint requests should be ad-
dressed at HIV and Retrovirology Branch, Centers for Disease Controlmay be critical to determining whether potential vaccines
should include a single strain, a recombinant circulating
form, or a cocktail of antigens from different HIV-1
strains. The importance of matching a vaccine candidate
to local circulating strains is unclear but evidence sug-
gests that cytotoxic T-lymphocyte cross-reactivity among
different HIV-1 subtypes will be an important component
of a single efficacious HIV vaccine (Cao et al., 1997;
Ferrari et al., 1997; Buseyne et al., 1998; McAdam et al.,
1998; Rowland-Jones et al., 1999). HIV-1 infection is more
prevalent and genetically complex in Africa than any-
where else in the world. Therefore, characterization of
the HIV-1 population is essential to our goal of develop-
ing an effective HIV vaccine for West Africa.
There is the danger of designing a vaccine based on
a unique isolate rather than the predominant circulating
strain. Obtaining comprehensive data on the pool of
circulating strains is critical for designing vaccines
based on local strains. For example, in Thailand, the
initial epidemic within injecting drug users (IDU) was
largely HIV-1 subtype B; a 1994 cross-section study (Wasi
et al., 1995) found that 80% of prevalent infections were
subtype B and 20% were subtype E. However, a 1995–
1998 prospective cohort study found that 80% of incidentthe major circulating viral strain.
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infections were subtype E (Subbarao et al., 2000; Van-us seq1550042-6822/02
ichseni et al., 2001). This change in the molecular epi-
demiology probably resulted in the use of bivalent sub-
type B/E envelope proteins in the current HIV-1 vaccine
trail.
HIV-1 has been genotypically divided into three dis-
tinctive groups: M, N, and O. Group M (for Major) com-
prises most of the HIV-1 strains that cause AIDS world-
wide and has been further subdivided into 9 different
subtypes (A–D, F–H, J, and K) (Janssens et al., 1997; Carr
et al., 1998b). Many mosaic or subtype recombinant
forms of HIV-1 have also been described and are be-
lieved to represent about 10% of all circulating HIV-1
strains (Gao et al., 1998; McCutchan et al., 1996; Robert-
son et al., 1997; Robertson et al., 1995a,b). In some
regions of the world, HIV-1 recombinant strains, now
designated as circulating recombinant forms (Robertson
et al., 2000), have established a high prevalence; they are
as common as the local subtypes and may play a major
role in the AIDS pandemic (Carr et al., 1998b). For in-
stance, in Senegal, Cameroon, Gabon, and Nigeria, 50–
85% of circulating strains are a recombinant form of
HIV-1 derived from subtypes A and G, called CRF02-AG
(Montavon et al., 2000). Other examples of inter-subtype
recombinants that have relative substantial prevalence
include the A/E strain in southeast Asia designated
CRF01-AE (Carr et al., 1996; Gao et al., 1996), subtype B/C
recombinants in China designated CRF07-BC (Su et al.,
2000) and CRF08-BC (Piyasirisilp et al., 2000), and a
subtype A/B form in Russia’s IDU population termed
CRF03-AB (Bobkov et al., 1998; Liitsola et al., 1998). The
presence of the subtype A/G recombinant form, CRF02-
AG, throughout West and Central Africa (Montavon et al.,
2000; Carr et al., 1998a; Nkengasong et al., 2000; Anders-
son et al., 1999; McCutchan et al., 1999; Peeters et al.,
2000; Toure-Kane et al., 2000) has major implications for
vaccine development in this region of high HIV-1 preva-
lence.
In this study, we sought to determine the best HIV-1
vaccine candidate for a targeted West African population.
We compared viral sequences derived from incident and
prevalent cases of HIV-1 infection and derived a consen-
sus sequence that clearly represents both circulating
plasma virus and cellular provirus. Furthermore, this
comparative analysis indicates that the best HIV-1 vac-
cine candidate for Abidjan, Coˆte d’Ivoire, and perhaps
other areas of West Africa, is closely related to the major
inter-subtype recombinant virus, CRF02-AG predominant
in this region.
RESULTS
We conducted a detailed biologic description and
characterization of HIV-1 recovered from 23 HIV-infected
persons in Abidjan, Coˆte d’Ivoire, 4 of whom were inci-
dent cases (Table 1). The p24 region of gag was se-
quenced from all strains, and sequence information was
obtained from either the circulating plasma virus (n 
14) or DNA provirus (n  9). All 23 sequences along
with reference sequences, including 7 circulating-recom-
binant form CRF02-AG strains from West and Central
Africa, were used to construct a phylogenetic tree (Fig.
1). HIV-1 subtype A represented the vast majority of the
specimens, accounting for 22 (95.7%) of the 23 se-
quences. One specimen (IC1435) clustered with subtype
B and D reference strains. The 22 subtype A strains and
the derived Abidjan consensus sequence clustered to-
gether, but two distinct secondary branches of subtype A
grouping were observed. Of the 22 subtype A strains, 19
clustered with the 7 CRF02-AG strains and the Abidjan
consensus sequence, while 3 appeared distinct and
clustered more closely with prototypic full-length subtype
A strains. The branch structure supporting the distinct
clustering within the subtype A grouping has a bootstrap
value of 83; the strains from Abidjan repeatedly remained
clustered, as shown in Fig. 1. Moreover, the tree topology
was similar whether neighbor-joining, neighbor-joining
with bootstrapping, or maximum-likelihood methodolo-
gies were used (data not shown). Pairwise gag p24
TABLE 1









IC098 FSW I RNA A/G n/a
IC200 FSW I RNA A/G n/a
IC896 FSW I Provirus A/G G
IC928 FSW I Provirus A/G G
IC737 ARV P RNA A/G G
IC745 ARV P RNA A/G n/a
IC763 ARV P RNA A/G G
IC764 ARV P Provirus A/G G
IC767 ARV P RNA A/G G
IC793 ARV P RNA A n/a
IC822 ARV P RNA A n/a
IC1291 ARV P Provirus A/G G
IC1351 ARV P RNA A/G n/a
IC1411 ARV P Provirus A/G G
IC1435 ARV P RNA B-D B-D
IC1509 ARV P RNA A/G G
IC1611 ARV P RNA A/G G
IC1739 ARV P RNA A/G B
IC1955 ARV P RNA A/G n/a
IC374 TB P Provirus A/G G
IC378 TB P Provirus A/G G
IC418 TB P Provirus A/G G
IC421 TB P Provirus A G
a FSW, female sex worker; ARV, persons starting antiretroviral ther-
apy; TB, tuberculosis patient.
b Source of nucleic acid for sequence analysis.
c Twenty-two gag p24 specimens were HIV-1 subtype A, but 19
specimens (denoted by A/G) cluster with A/G reference strains; n/a,
inadequate sequence available for analysis.
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nucleotide sequence divergence among all 22 Abidjan
subtype A isolates ranged from 1.7 to 11.4%. Excluding 1
distinct strain (IC763) that clustered with a CRF02-AG
reference strain from the analysis reduced the pairwise
gag p24 nucleotide sequence divergence range from 1.7
to 6.7%. The sequence divergence among the 3 strains in
the other secondary subtype A branch was 2.2 to 5.9%.
The protease region of the pol gene was sequenced in
16 of 23 specimens to confirm the presence of inter-
subtype recombinant HIV sequences and potential
FIG. 1. Phylogenetic relationships of newly characterized Coˆte d’Ivoire HIV-1 gag p24 sequences in comparison to representatives from 8 HIV-1
group M subtypes and 2 circulating recombinant forms, including 7 CRF02-AG. The gag p24 tree was generated by using the neighbor-joining method
with nucleotide distance datum sets calculated by Kimura’s two-parameter approach. Numbers at the branch nodes connected with subtypes indicate
bootstrap values. The distinct HIV-1 subtypes (A–D, F–H, J), CRF (AE and AG), and new Coˆte d’Ivoire sequences (IC) are delineated. The tree was
rerooted by using chimpanzee simian immunovirus (SIV-cpz) as an outgroup. The scale bar indicates an evolutionary distance of 0.10 nt per position
in the sequence. Vertical distances are for clarity only.
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CRF02-AG strains. Seven specimens yielded inadequate
sequence for analysis of the pol region. All 16 sequences
along with Group M reference subtypes including CRF
from West Africa were used to construct a phylogenetic
tree (Fig. 2). By phylogenetic analysis, 14 of 16 se-
quences were determined to be subtype G in protease,
FIG. 2. Phylogenetic analysis of newly characterized Coˆte d’Ivoire HIV-1 pol protease sequences in comparison to representatives from 8 HIV-1
group M subtypes and 6 CRF02-AG. The prot tree was generated by using the neighbor-joining method with nucleotide distance datum sets
calculated by Kimura’s two-parameter approach. Numbers at the branch nodes connected with subtypes indicate bootstrap values. The distinct HIV-1
subtypes (A–D, F–H, J), CRF02-AG, and new Coˆte d’Ivoire sequences (IC) are delineated. The tree was rerooted by using chimpanzee simian
immunovirus (SIV-cpz) as an outgroup. The scale bar indicates an evolutionary distance of 0.10 nt per position in the sequence. Vertical distances
are for clarity only. Sixteen representative Abidjan HIV-1 protease sequences were aligned with 22 HIV-1 reference isolates of diverse geographical
origin and an outlier SIV strain SIVCPZ.
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similar to CRF02-AG strains and indicative of an A/G
recombinant strain. The 14 protease subtype G strains
from Abidjan clustered together with the 6 CRF02-AG
reference strains; this branch structure has bootstrap
support of 83%. Pairwise protease sequence divergence
among all the Abidjan protease subtype G isolates
ranged from 0.7 to 11.9%. Two of the 16 specimens
(IC1739 and IC1435) did not cluster with subtype G in
protease analysis. Specimen IC1739 clustered with sub-
type B reference strains, suggesting an A/B recombinant
strain. Specimen IC1435 clustered with subtype B and D
reference strains in the pol protease region, identical to
the findings in the gag p24 region.
Prior to translation of the 23 DNA sequences, all gag-
derived sequences were aligned, generating an Abidjan
consensus nucleotide sequence. The Abidjan consen-
sus nucleotide sequence was 99% identical to the inter-
subtype recombinant CRF02-AG and only one nonsyn-
onymous nucleotide substitution was observed (data not
shown). Table 2 summarizes their homology to the Abid-
jan consensus nucleotide sequence. The homology
range for the 22 subtype A strains was 93.4–99.2% with a
mean of 96.9%. The single nonsubtype A strain (IC1435)
was less homologous (91.5%) to the consensus se-
quence. The 4 incident and 19 prevalent strains were
found to be 97.1 and 96.6% homologous to Abidjan con-
sensus sequence, respectively. DNA homology for the 14
circulating plasma virus and 9 provirus sequences was
very similar, 96.6 and 96.8%, respectively. The overall
homology to the prototype A/G recombinant CRF02-AG
(IbNG) sequence for all 23 DNA sequences was 96.6%.
All 23 gag p24 sequences were translated and
aligned. A consensus protein-coding sequence (Abidjan
sequence) comprising 148 amino acids was subse-
quently derived (Fig. 3). Virtually all of the codons (147 of
148) in the Abidjan sequence were identical to the inter-
subtype recombinant strain, CRF02-AG. At codon posi-
tion 7, a Gly-to-Ala alteration was observed between the
Abidjan sequence and the CRF02-AG reference se-
quence. All 23 Ivorian sequences were Ala at this posi-
tion due to a single nucleotide difference (G-to-C
change) in the second position of the codon. Minor
codon variations among the 23 strains as compared to
the reference CRF02-AG were observed throughout the
translated sequence, but percentage variability at each
position in the Abidjan consensus sequence was limited
(Fig. 4). There was complete homology at approximately
FIG. 3. Abidjan consensus amino-acid sequence of gag p24 derived from 23 Coˆte d’Ivoire HIV-1 strains. Approximately 64% (444 bp) of gag p24
was translated and aligned. Four incident and 19 prevalent strains were examined. CRF02.AG sequence is shown for comparison. The number and
single amino-acid code describe the number of changes and the alternate amino acids detected among the 23 strains. Asterisks denote no change
from the Abidjan consensus sequence.
TABLE 2
DNA Homology to Abidjan Consensus Sequence
Strains Range Average
Circulating plasma virus n 9 91.1–98.8% 95.8%
Provirus n 14 94.6–98.4% 96.7%
Incident n 4 95.7–96.9% 96.3%
Prevalent n 19 91.1–98.8% 96.1%
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80% of the codons in all 23 sequences, and there were
less than two changes per codon in 90% of the Abidjan
consensus sequence. Furthermore, 3 or more individual
strains differed at any one particular amino acid in less
than 10% of the codon positions.
To compare sequence similarities between incident
and prevalent strains, gag consensus sequences were
generated for isolates from each group. The incident
strain consensus coding sequence was based on the 4
incident specimens (IC098, IC200, IC896, and IC928),
and the prevalent strain consensus sequence was gen-
erated using the 19 prevalent strains (Fig. 3). Surprisingly,
both the incident and prevalent strain consensus se-
quences were identical to each other and to the Abidjan
consensus sequence. Two of the 4 incident strains were
99% identical to the Abidjan consensus sequence, and
the other 2 strains showed either three or five changes
along the entire 148-amino-acid sequence (Fig. 5a). Six
of 19 prevalent strains were 99% identical to the Abidjan
sequence, and the remaining prevalent strain sequences
were at least 95% identical (Fig. 5a).
Fourteen gag p24 sequences derived from circulating
plasma virus were translated and aligned to generate a
consensus sequence. When compared, complete homol-
ogy between the circulating virus consensus sequence
and the Abidjan consensus sequence was observed.
Alignment of the translated sequences showed limited
strain-to-strain variability; 10 of 14 sequences had five or
fewer changes among the 148 codons (Fig. 5b). A provi-
ral DNA-derived (9 strains) consensus sequence was
also generated. Again, complete homology to the Abid-
jan consensus sequence and limited strain-to-strain vari-
ability was observed (Fig. 5b). When the circulating virus
and proviral DNA-derived consensus sequences were
compared, they were identical to each other.
DISCUSSION
Several key issues regarding an HIV-1 DNA vaccine
candidate for West Africa remain unresolved. We consid-
ered whether the candidate virus should be recovered
from incident strains or the most prevalent HIV-1 strain,
and whether circulating plasma virus, archived HIV-1
provirus recovered from PBMCs, or both should be in-
cluded.
In this report, we describe the first detailed analysis of
the current population of circulating prevalent and inci-
dent HIV-1 strains in Abidjan and propose our most likely
vaccine candidate for this region of West Africa. HIV-1
subtype A was previously shown to be the predominant
strain (95%) circulating within Abidjan, Coˆte d’Ivoire (El-
lenberger et al., 1999), and the interior of this West
African country (Nkengasong et al., 2000). Based on
partial env sequencing, this subtype A virus was shown
to be phylogenetically distinct from other subtype A
strains observed in East Africa (Ellenberger et al., 1999).
A recent report has extended this initial description to
indicate that the majority of strains from Coˆte d’Ivoire
FIG. 4. Amino acid differences from the derived Abidjan consensus
sequence. The number of changes per amino acid from the Abidjan
consensus sequence as determined for each collected specimen is
examined.
FIG. 5. (a) Comparison of incident and prevalent per strain amino-
acid changes. Four incident (striped bars) and 19 prevalent (dotted
bars) strains are compared. (b) Comparison of provirus and circulating
plasma per strain amino acid changes. Fourteen circulating plasma
RNA (dashed bars) sequences and 9 provirus (bars with block pattern)
are compared. The number of changes per strain from the Abidjan
consensus is noted in both a and b.
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were recombinant A/G, CRF02-AG (Carr et al., 1999). We
recently completed a similar phylogenetic analysis of the
same subtype A viral strains circulating within Abidjan
while including the inter-subtype recombinant virus
CRF02-AG and found that they cluster together (data not
shown). Therefore, in our initial analysis of strains from
this region of Africa, many were classified as subtype A
(Howard et al., 1994; Howard and Rasheed, 1996) rather
than recombinants because CRF02-AG is a complex mo-
saic virus with alternating A and G sequences in which
both gag and env derive largely from subtype A.
Our current sample set of 23 specimens from Coˆte
d’Ivoire was examined in both the gag and pol regions of
the HIV genome to further confirm any recombinant
forms. In this analysis, greater than 95% of the speci-
mens were shown to be subtype A in the gag region, and
19 of 22 specimens clustered distinctly with CRF02-AG
strains. The protease region of pol in CRF02-AG is sub-
type G, and 87.5% of the strains in this study set are
subtype G, consistent with the inter-subtype recombinant
and CRF02-AG-mosaic structure. The CRF02-AG preva-
lence estimate for the relatively small sample size is 78%
and despite an error of prevalence greater than 10%, our
estimate is within the 50–85% range for CRF02-AG re-
combinants observed in West Africa (Montavon et al.,
2000). A systematic selection bias with respect to sub-
type appears unlikely since the samples were indepen-
dently collected at three clinics without known dates of
infection. Furthermore, the lack of significant clustering
by clinic or period in the phylogenetic analyses suggests
that infections are being transmitted in a broad, hetero-
geneous manner in Abidjan. Our data confirm the geo-
graphic dispersion of CRF02-AG in Coˆte d’Ivoire and its
continuing transmission within Abidjan, as evidenced by
our finding that all 4 incident HIV-1 strains were inter-
subtype recombinant A/G virus.
In earlier studies, investigators have reported a num-
ber of recombinant or mosaic HIV-1 genomes worldwide,
including some form of recombination by eight subtypes
of HIV-1 group M. In this study, we have identified two
recombinant patterns in our limited sampling in Abidjan,
including A/G and A/B (strain ICE1739). Based on the
discordant subtype results between partial gag and
pol sequences, greater than 90% of the 23 strains in
our study are recombinant viruses. This percentage
exceeds the global estimations on circulating recom-
binant viruses as well as the overall percentages of 51
to 75% shown in other areas of West and West Central
Africa (Montovan et al., 2000). Surveillance for HIV
genetic subtypes is important for vaccine development
and is essential for refining diagnostic and treatment
strategies. The introduction of antiretroviral treatment
in parts of Africa, ultimately to include protease inhib-
itors, raises concerns because HIV-1 subtype G virus
has decreased susceptibility to protease inhibitors
(Descamps et al., 1998). Importantly, the complex mo-
saic CRF02-AG virus is subtype G in the protease
gene.
Of course, the central issue for vaccine development
remains determining how much the diversity of HIV se-
quences affects immune recognition of the encoded pro-
teins and, consequently, whether vaccines based on one
strain will protect against others. Investigators have
shown significant cytotoxic T-lymphocyte cross-reactivity
for different HIV subtypes (Cao et al., 1997; Ferrari et al.,
1997; Buseyne et al., 1998; McAdam et al., 1998; Row-
land-Jones et al., 1999); thus a vaccine based on a single
subtype or circulating recombinant form may be broadly
applicable. Although the correlates of immune protection
in HIV-1 infection are unknown, matching the local strain
may maximize the chance of success for a candidate
vaccine. In other regions of the world, a consensus
sequence based on circulating prevalent strains may
indeed differ from a sequence derived from incident
strains. Furthermore, a consensus sequence derived
from archived provirus may ultimately differ from circu-
lating plasma virus, especially in prevalent cases late in
infection, depending on the duration of the immunocom-
petent period (Lukashov et al., 1995). Our data show that
regardless of the compartment, each consensus se-
quence (plasma and provirus) is identical to the Abidjan
consensus sequence generated from the sample collec-
tion overall, including three populations in Abidjan, Coˆte
d’Ivoire: female sex workers (FSW), tuberculosis patients
(TB), and persons starting antiretroviral therapy. Recog-
nizing that our data represent a snapshot of the virus
population in each person, and that the rate of HIV-1
intrahost evolution may be a function of the host selec-
tive forces acting on the replicating virus (Delwart et al.,
1997), we did not compare intrahost provirus and RNA
since the consensus sequence was identical for all in-
terhost viral compartments. Our data also show that
regardless of its derivation, the consensus derived from
these Ivorian strains is essentially homologous to
CRF02-AG. The recombinant strain CRF02-AG or Abidjan
consensus sequence based on the local strains may
increase the chance for success in vaccinated persons
within West Africa, assuming the vaccine is HIV-1 sub-
type-specific. Furthermore, Coˆte d’Ivoire may be a good
place for a vaccine efficacy trial because the vaccine will
be challenged by a limited diversity of strains.
Determining whether a vaccine will protect against
diverse strains of HIV is critical. Although a vaccinee
may have a diminished immune response to an un-
matched HIV strain, a weaker response might still be
sufficient to afford some level of protection. The im-
portance of matching vaccine immunogens to circulat-
ing HIV strains will not be fully understood until results
from vaccine trials in areas with multiple subtypes
become available.
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MATERIALS AND METHODS
Study samples
Samples for this study were collected from persons
identified in three populations in Abidjan, Coˆte d’Ivoire:
FSW, TB, and persons starting antiretroviral therapy. In-
formed consent was obtained from all study participants
under a protocol approved by CDC and local Internal
Review Boards. Four FSWs (incident cases) were in-
cluded from a group of HIV-seronegative FSWs that
Project Retro CI was following in a microbicide clinical
trial initiated in 1994 at a confidential clinic in Abidjan.
Incident cases were determined by seroconversion to
HIV within 12 weeks of last negative blood sample. Four
samples were collected from TB patients who were par-
ticipating in an HIV counseling and testing service that
was made available in 1994 at all TB treatment centers in
Coˆte d’Ivoire. Fifteen samples were collected from per-
sons seeking care in the UNAIDS Drug Access Initiative
(UNAIDS DAI) which was initiated in 1998. The 19 prev-
alent cases were selected from TB patients and persons
beginning antiretroviral therapy in the UNAIDS DAI with
CD4 counts 500 per microliter. Blood samples for lym-
phocyte separation were collected from the study partic-
ipants. Specimens were tested for antibodies to HIV-1/2
as described previously (Nkengasong et al., 1999).
Genetic subtyping
HIV-1-specific polymerase chain reaction (PCR) was
done on uncultured peripheral blood mononuclear cells
(PBMCs). Reverse transcriptase (RT)-PCR followed by
DNA PCR was done on HIV-1 RNA recovered from
plasma. The conditions for nested PCR and primer sets
for PCR amplification of protease (297 bp) and gag p24
(444 bp) have been described elsewhere (Janini et al.,
1996; Brennan et al., 1997). The standard primer for gag
p24 gene RT-PCR amplification was P2470R (5 CCC TGR
CAT GCT GTC ATC A). Thermal cycling conditions for
RT-PCR were: 42°C, 15 min; 99°C, 5 min; and 4°C, 5 min.
DNA sequencing was completed using the ABI Prism
dye terminator cycle sequencing reaction kit (Perkin-
Elmer, Foster, CA) with Amplitaq DNA polymerase FS
and automated sequencer ABI Model 373 (Applied Bio-
systems, Foster City, CA). HIV-1 sequences were derived
from the HIV gag p24 and pol protease regions. Both
strands of the PCR products were sequenced directly.
Sequence data were analyzed using Sequencher 3.0
software (Gene Codes, Ann Arbor, MI). Nucleic acid
sequences were trimmed to equivalent lengths and
aligned with representative HIV-1 group M subtypes and
multiple CRF02-AG strains available in the Los Alamos
database. The neighbor-joining method included in the
Phylip 3.5c software package (Courtesy of Joe Felsen-
stein, University of Washington, Seattle, WA) was used to
construct the phylogenetic trees.
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